U.S. markets open in 4 hours 46 minutes

Reckitt Benckiser Group plc (3RB.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
80.00+1.00 (+1.27%)
As of 09:57AM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close79.00
Bid79.90 x N/A
Ask80.20 x N/A
Day's Range79.10 - 80.00
52 Week Range64.30 - 82.10
Avg. Volume627
Market Cap57.153B
Beta (5Y Monthly)0.10
PE Ratio (TTM)15.87
EPS (TTM)5.04
Earnings DateN/A
Forward Dividend & Yield2.05 (2.60%)
Ex-Dividend DateAug 04, 2022
1y Target EstN/A
  • Financial Times

    Reckitt gains from rising medicine sales as Covid-19 beds in

    Strepsils-maker and rival Haleon benefit from over-the-counter treatments boost from Omicron, colds and flu

  • Financial Times

    Haleon/Reckitt Benckiser: Covid offers cold cure makers a long-lasting boost

    Colds and flu put on a lockdown disappearing act. It buoyed Haleon’s half-year results and those of rival Reckitt Benckiser on Wednesday. It is a similar story from Haleon, which reported that sales of its Theraflu medicine more than doubled.

  • Benzinga

    Reckitt Lifts Annual Forecast On Higher Prices, Baby Formula Shortage

    Reckitt Benckiser Group PLC (OTC: RBGLY) said Q2 like-for-like revenue rose 11.9% on a constant currency basis, beating the 6.8% growth analysts had expected in a company-supplied poll. Reckitt hiked prices 9.7% in the quarter, while sales volumes were up 2.2%. Q2 sales increased 5.9% on constant currency to £3.46 billion, including a 3.3% boost from sales of its Enfamil baby formula amid a shortage of supplies in the U.S. after Abbott Laboratories (NYSE: ABT) recalled dozens of brands in Februa